[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hepatitis A Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 30 pages | ID: HA24A6389A24EN
VPAResearch

US$ 1,529.00 US$ 1,699.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Hepatitis A Drug pipeline report- 2020 is an annual R&D review of Hepatitis A pipeline candidates. The report presents the current status of all major Hepatitis A therapeutic compounds. Detailed insights into Hepatitis A pipeline development, current status, companies, drug profiles and Hepatitis A preclinical and clinical trials are included.

2020 Hepatitis A Pipeline Market Insights
Hepatitis A disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Hepatitis A therapies, pipeline by phase and others are included.

Hepatitis A pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Hepatitis A Therapeutic Drug candidates
Both active and inactive Hepatitis A pipeline drug candidates are included in the report

Hepatitis A Clinical Trials and preclinical Studies
Hepatitis A In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Hepatitis A pipeline market developments
Hepatitis A Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Hepatitis A pipeline companies in active development
The report analyzes Hepatitis A pipeline of the below companies-

Beijing Minhai Biotechnology Co Ltd, Boryung Pharmaceutical Co Ltd, Indian Immunologicals Ltd, Zydus Cadila Healthcare

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
4 Companies investing in Hepatitis A pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Hepatitis A pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included
1. HEPATITIS A PIPELINE MARKET INSIGHTS, 2020

1.1 Hepatitis A Disease Overview
1.2 Hepatitis A Drug Pipeline Snapshot, 2020
  1.2.1 Hepatitis A Pipeline Drugs by Phase
  1.2.2 Hepatitis A Pipeline Drugs by Company
  1.2.3 Hepatitis A Pipeline Drugs by Mechanism of Action
  1.2.4 Hepatitis A Pipeline Drugs by Route of Administration

2. HEPATITIS A COMPANY WISE PIPELINE DETAILS

Beijing Minhai Biotechnology Co Ltd Hepatitis A Pipeline Drugs
  Company Profile
  Drug Candidate Details
Boryung Pharmaceutical Co Ltd Hepatitis A Pipeline Drugs
  Company Profile
  Drug Candidate Details
Indian Immunologicals Ltd Hepatitis A Pipeline Drugs
  Company Profile
  Drug Candidate Details
Zydus Cadila Healthcare Hepatitis A Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. HEPATITIS A DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. HEPATITIS A PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts


More Publications